OSE Immunotherapeutics SA (LON:0RAD)

London flag London · Delayed Price · Currency is GBP · Price in EUR
4.392
-0.048 (-1.08%)
At close: Feb 10, 2026
Market Cap87.27M -24.6%
Revenue (ttm)1.55M -95.8%
Net Income-28.37M
EPS-1.29
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6
Average Volume194
Open4.392
Previous Close4.440
Day's Range4.392 - 4.392
52-Week Range4.250 - 7.640
Beta0.51
RSI34.19
Earnings DateMar 27, 2026

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 64
Stock Exchange London Stock Exchange
Ticker Symbol 0RAD
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements